Discover the latest progress of OxTium Technology in AI bioscience.
OxTium Technology founder Jin Yongcheng has been selected for 36Kr's 2026 Under36 Science Innovation List. As a representative of the AI for Science track, he was recognized for breakthrough explorations in Embodied Science. Only 36 science innovators nationwide were selected, with over two-thirds directly related to AI or robotics, and an average age of about 33.
Read moreOxTium Technology completes nearly 100 million RMB Series A funding led by GTJA Investment. Funds will be used for Physical-AI infrastructure development, BioFord Agent embodied autonomous research platform iteration, and global market expansion. GTJA Investment has focused on healthcare for 24 years, managing over 23 billion RMB in assets and helping 30 medical companies go public.
Read moreOxTium Technology and Yijiaen Intelligent Technology made their debut as China's first full-stack 'AI + Biomanufacturing' solution alliance at the 16th International Bio-Fermentation Conference, becoming the only exhibitor to realize AI integration in bio-fermentation scenarios. They brought an AI intelligent control screen and DCS system to the venue, demonstrating autonomous operation and intelligent optimization of the entire fermentation process.
Read moreOxTium Technology has been officially recognized as a National High-Tech Enterprise, another major honor following its selection for the "Open Bidding" program. The certification involves strict review standards for intellectual property, R&D investment, and technology commercialization, fully acknowledging OxTium's technological innovation, core competitiveness, and sustainable development potential in the AI for Science field.
Read moreThe OEHI delegation visited Peking University Shenzhen Graduate School. OxTium Technology co-founder Zhou Tianyao attended as head of the AISI secretariat. The meeting focused on new cross-border AI4S collaboration models, integrating computing continuum from edge to HPC to boost China-Europe research synergy.
Read moreThe PKU-AI4S Innovation Challenge Phase I, co-organized by Peking University School of AI for Science and OxTium Technology, has successfully concluded. The competition focused on four AI4S directions: biology, chemistry, materials, and comprehensive topics. PKU students tackled cutting-edge challenges such as protein structure prediction and retrosynthetic route planning, fostering interdisciplinary innovation through industry-academia integration.
Read moreOxTium Technology showcased at the 4th SynBioChina Synthetic Biology Conference. CTO Dr. Deng Siwei delivered a keynote, proposing that AI is evolving from a supporting tool into a "digital nervous system" for biomanufacturing, building a full-chain digital-intelligent closed-loop solution integrating R&D, experimentation, and production, becoming the highlight of the event.
Read moreThe U8 Youth Innovation Forum brought together Fields Medalists, Turing Award winners, and top global scholars. OxTium Technology unveiled the BioFord Agent research infrastructure, which automatically completes experiment design, workflow decomposition, and parameter calculation with a single command. OxTium founder Jin Yongcheng, also a co-founder of U8, showcased how AI ends inefficient repetitive 'slow experiments,' drawing significant attention from distinguished guests.
Read moreOxTium Technology completes tens of millions in Pre-A+ round, invested by Nanshan Strategic Investment, the strategic direct investment platform of Shenzhen Nanshan District. Within months, it has gained favor from Sequoia China Seed Fund, CDF-Capital, etc., with cumulative funding nearing 100 million RMB. Previously, it also received tens of millions in special funds for high-level talents from Shenzhen. Capital continues to increase bets on the AI for BioScience track.
Read moreOxTium Technology completes tens of millions in Pre-A round, led by CDF-Capital with Jiangxi Financial Holdings following. The company, with its GeneLLM large model, BioFord™ platform, and BioFord Agent™ intelligent agent system, spans CDF-Capital's AI and healthcare tracks, solidifying its position as an AI for BioScience pioneer.
Read moreIn response to the seven ministries' 'AI + Industry Large Model' strategy, OxTium Technology has partnered with Yijiaen Intelligent Technology to focus on the 'Intelligent Bioprocessing Project,' integrating AI algorithms with online sensing technology to create a replicable 'Lighthouse Factory' benchmark, empowering intelligent biomanufacturing upgrades.
Read moreOxTium Technology has completed a tens of millions RMB Angel+ round led by Sequoia China Seed Fund, following previous support from Xiantong Capital, Leaguer Venture Capital, and Shenzhen High-Level Talent Special Fund. The new funds will accelerate AI for BioScience R&D and market expansion, aiming to build a globally leading bioscience large model foundation.
Read moreOxTium Technology's GeneLLM large model published in Nature sub-journal npj Digital Medicine! In collaboration with BGI, Zhejiang University School of Medicine, and others, it is the world's first to combine Transformer with multi-omics cfDNA+cfRNA to predict preterm birth, achieving an AUC of 0.890, significantly outperforming single-data models, opening a new direction for precision obstetrics.
Read moreOxTium Technology creates a fully no-code AI platform BioFord™ for bioscience researchers, integrating hundreds of specialized large models covering basic research, medical diagnostics, and biomanufacturing to lower the barriers to scientific research.
Read moreGeneLLM® employs a 'pre-training and fine-tuning' mechanism to enable cross-domain knowledge transfer. Its lightweight architecture supports high-precision analysis with small samples, covering medical diagnostics, biological breeding, environmental monitoring, and more, significantly reducing costs and improving efficiency.
Read moreCCTV spotlights OxTium Technology's GeneLLM™️, a 1.5-billion-parameter model decoding RNA omics for early AD detection. Three breakthroughs define new standards for bio-AI, driving research from hypothesis-driven to data-intelligence-driven.
Read moreGeneLLM™ launches Bioford™ training-inference all-in-one, supporting A100/Ascend/Kunpeng and other domestic configurations for local deployment. From basic research to medical diagnosis, it drives AI healthcare with professional expertise, ending the 'deviation' of general models.
Read morePeking University Hospital and OxTium Technology have reached a strategic cooperation to jointly promote the GeneLLM™ large model to empower basic cancer research. Focusing on gastric cancer and colorectal cancer, integrating cfRNA and multi-omics data to improve early risk detection accuracy and accelerate medical translation.
Read more